What causes this growth? “We are developing new drugs against various diseases. Our research continously is in progress, so we have to do more tests and therefore need more people. Eventually, we want to become the largest biotechnology company in Europe,” says Fox.
Today, Galapagos is not yet selling drugs. “This will change in 2020, when we will bring our rheumatoid arthritis agent Filgotinib on the market. Filgotinib is a pill that the patient has to take once a day. It works better than the current injections for rheumatoid arthritis. If you take a pill, your pain should be relieved within one week,” says Fox.
Read more about Galapagos.